Rheumatoid Arthritis (RA) - Market Insights, Epidemiology and Market Size Forecast-2020" Reports provides an overview of the disease and global market size of the Rheumatoid Arthritis (RA) for the United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. It also includes global historical and forecasted epidemiological data for the diagnosed incident cases of Rheumatoid Arthritis (RA) from 2010-2020.Rheumatoid arthritis is an autoimmune disease in which the body's immune system – which normally protects its health by attacking foreign substances like bacteria and viruses – mistakenly attacks the joints. RA affects between 0.5 and 1% of adults in the developed world with between 5 and 50 per 100,000 people newly developing the condition each year. RA reduces lifespan on average from three to twelve years. It is unknown how these agents compare to the current biologics because there are no head-to-head trials to date. Most studies are conducted on patients who have already failed current therapy, suggesting that the likely niche for these newer pipeline agents may be for RA that is more severe.